Continued funding for special studies

Nina Schwalbe

GAVI Alliance Board meeting
Washington, DC, USA, 12-13 June 2012
Special studies background

- Funding for special studies provided under the ADIPs:
  - Pneumo (US$ 30m) focused on evidence generation and disease advocacy
  - Rota (US$ 50m) included significant phase IV investment for data to support SAGE recommendation
  - Hib Initiative (US$ 30m) designed to promote Hib disease burden awareness and conduct studies including phase IV, impact, etc
  - AVI TAC Special Studies – (US$ 11m) for additional studies required for pneumococcal and rotavirus vaccine roll-out
### GOAL

Scientific and economic studies to support decision-making and assess impact of rotavirus & pneumococcal vaccines

### OBJECTIVES

1. Generate evidence base on the economic value of PCV and rotavirus vaccines.

2. Generate evidence base of health impact attributed to vaccine introduction.

3. Synthesise evidence base for policymakers and health officials on the burden of rotavirus and PNC diseases and impact of vaccines.
Urgent studies submitted by AVI-TAC and recommended by PPC

Pneumococcal conjugate vaccines

1. Case control study to estimate effectiveness against invasive disease in South Africa (US$ 2.0 million)

2. Vaccine impact study in Kenya (US$ 5.9 million)

Rotavirus vaccines

1. Assessment of the vaccine effectiveness of the multivalent in Rwanda (US$ 0.7 million)

2. Assessment of the vaccine effectiveness of the monovalent rotavirus vaccine in Ghana (US$ 0.7 million)
Additional study requested by the PPC

- In view of the recent SAGE recommendation to loosen age restrictions for the delivery of rotavirus vaccines, provide funding to support surveillance for intussusception at select sites following introduction
- AVI-TAC proposal undergoing peer review
- Total additional request of US$ 1.8 million over four years
Next steps

- If the urgent studies are approved by the Board, GAVI will award funding to the AVI-TAC consortium through the existing agreement.

- Through the business planning process, and drawing on the areas for research identified as high priority by the expert group, the Secretariat will identify special studies which should be considered for funding in 2013-2015.
Recommendations:

The Board is recommended to:

- **Approve** an amount of up to US$ 9.3 million for AVI-TAC to continue two urgent pneumococcal studies and conduct two urgent rotavirus studies over a three year period, through 2015; and

- **Approve**, subject to the Secretariat receiving satisfactory peer review reports, an amount of US$ 1.8 million for AVI-TAC to conduct a study to monitor the impact of the SAGE recommendation on widening age restrictions related to rotavirus vaccine delivery.